Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs

被引:21
|
作者
Finlay, Andrea K. [1 ,2 ]
Ellerbe, Laura S. [1 ]
Wong, Jessie J. [1 ,3 ]
Timko, Christine [1 ,3 ]
Rubinsky, Anna D. [4 ,5 ]
Gupta, Shalini [1 ]
Bowe, Thomas R. [1 ]
Burden, Jennifer L. [6 ]
Harris, Alex H. S. [1 ,7 ]
机构
[1] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[2] Dept Vet Affairs, Natl Ctr Homelessness Vet, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[3] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Menlo Pk, CA 94025 USA
[4] Univ Calif San Francisco, Kidney Hlth Res Collaborat, 500 Parnassus Ave, San Francisco, CA 94143 USA
[5] San Francisco VA Med Ctr, 500 Parnassus Ave, San Francisco, CA 94143 USA
[6] Vet Hlth Adm, Dept Vet Affairs, 1970 Roanoke Blvd,116A, Salem, VA 24153 USA
[7] Stanford Univ, Sch Med, Dept Surg, Alway Bldg,Room M121,300 Pasteur Dr, Stanford, CA 94305 USA
关键词
Alcohol-related disorders; Alcohol dependence; Pharmacotherapy; Veterans; Residential treatment; MENTAL-HEALTH; VETERANS; IMPLEMENTATION; DEPENDENCE; SETTINGS;
D O I
10.1016/j.jsat.2017.03.005
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Among US military veterans, alcohol use disorder (AUD) is prevalent and in severe cases patients need intensive AUD treatment beyond outpatient care. The Department of Veterans Affairs (VA) delivers intensive, highly structured addiction and psychosocial treatment through residential programs. Despite the evidence supporting pharmacotherapy among the effective treatments for AUD, receipt of these medications (e.g., naltrexone, acamprosate) among patients in residential treatment programs varies widely. In order to better understand this variation, the current study examined barriers and facilitators to use of pharmacotherapy for AUD among patients in VA residential treatment programs. Semi-structured qualitative interviews with residential program management and staff were conducted and the Consolidated Framework for Implementation Research was used to guide coding and analysis of interview transcripts. Barriers to use of pharmacotherapy for AUD included cultural norms or philosophy against prescribing, lack of access to willing prescribers, lack of interest from leadership, and perceived lack of patient interest or need. Facilitators included cultural norms of openness or active promotion of pharmacotherapy; education for patients, program staff and prescribers; having prescribers on staff, and care coordination within residential treatment and with other clinic settings in and outside VA. Developing and testing improvement strategies to increase care coordination and consistent support from leadership may also yield increases in the use of pharmacotherapy for AUD among residential patients. Published by Elsevier Inc
引用
收藏
页码:38 / 43
页数:6
相关论文
共 50 条
  • [21] Barriers and Facilitators to Substance Use Disorder Treatment: An Overview of Systematic Reviews
    Farhoudian, Ali
    Razaghi, Emran
    Hooshyari, Zahra
    Noroozi, Alireza
    Pilevari, Azam
    Mokri, Azarakhsh
    Mohammadi, Mohammad Reza
    Malekinejad, Mohsen
    SUBSTANCE ABUSE-RESEARCH AND TREATMENT, 2022, 16
  • [22] Pharmacotherapy for Alcohol Use Disorder: Current and Emerging Therapies
    Swift, Robert M.
    Aston, Elizabeth R.
    HARVARD REVIEW OF PSYCHIATRY, 2015, 23 (02) : 122 - 133
  • [24] Facilitators and barriers to intervening for problem alcohol use
    Tsai, Yun-Fang
    Tsai, Mei-Chu
    Lin, Yea-Pyng
    Weng, Chih-Erh
    Chen, Ching-Yen
    Chen, Min-Chi
    JOURNAL OF ADVANCED NURSING, 2010, 66 (07) : 1459 - 1468
  • [25] Facilitators and barriers to interagency collaboration in mother-child residential substance abuse treatment programs
    Iachini, A. L.
    DeHart, D. D.
    McLeer, J.
    Hock, R.
    Browne, T.
    Clone, S.
    CHILDREN AND YOUTH SERVICES REVIEW, 2015, 53 : 176 - 184
  • [26] Transitioning From Detoxification to Substance Use Disorder Treatment: Facilitators and Barriers
    Timko, Christine
    Schultz, Nicole R.
    Britt, Jessica
    Cucciare, Michael A.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 70 : 64 - 72
  • [27] Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease
    Stoklosa T.M.
    Morley K.C.
    Volovets A.
    Haber P.S.
    Current Addiction Reports, 2018, 5 (2) : 287 - 296
  • [28] Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review
    Hyland, Colby J.
    McDowell, Michal J.
    Bain, Paul A.
    Huskamp, Haiden A.
    Busch, Alisa B.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2023, 144
  • [29] Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings
    Haley, Sean J.
    Pinsker, Erika A.
    Gerould, Heather
    Wisdom, Jennifer P.
    Hagedorn, Hildi J.
    SUBSTANCE ABUSE, 2019, 40 (04) : 501 - 509
  • [30] Pharmacotherapy for Alcohol Dependence: Perceived Treatment Barriers and Action Strategies Among Veterans Health Administration Service Providers
    Harris, Alex H. S.
    Ellerbe, Laura
    Reeder, Rachelle N.
    Bowe, Thomas
    Gordon, Adam J.
    Hagedorn, Hildi
    Oliva, Elizabeth
    Lembke, Anna
    Kivlahan, Daniel
    Trafton, Jodie A.
    PSYCHOLOGICAL SERVICES, 2013, 10 (04) : 410 - 419